IRB approved. Odds ratios and Fisher tests were utilized to examine trends in this population. RESULTS: Seventeen percent (35/204) of the CVID patients had a diagnosis of cancer, with roughly half of those cases being leukemia/ lymphoma (n517). The second most common cancer type was skin cancer (n58). Pediatric onset of CVID symptoms (defined as symptom onset at <18 years of age) was protective against cancer development (OR52.41, p50.04), especially for females (OR 66.7, p50.005) . A delay in diagnosis from CVID symptom onset of greater than 10 years correlated with 3 fold increased risk of cancer development (p<0.005), while early diagnosis within 5 years was protective (OR56.67, p<0.005). A positive family history of cancer was seen in only 32% of the CVID patients (n565). 14% (n55) patients with CVID and cancer were deceased. CONCLUSIONS: Cancer is a well-known comorbidity of CVID, however, this is the first study to establish the protective effect of pediatric age at CVID symptom onset for cancer development and the significantly increased risk of cancer with a delay in diagnosis of CVID after symptom onset. Icahn School of Medicine at Mount Sinai, New York, NY. RATIONALE: Lymphoproliferative disease in common variable immunodeficiency (CVID) is heterogeneous in pathogenesis and ranges from non-malignant lymphoid hyperplasia to lymphoma.
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METHODS:
The Unites States Immunodeficiency Network (USIDNET) patient registry, which is a multi-site registry of de-identified patient data, was queried for lymphoproliferative disease reported in the CVID patients in the registry. Diagnoses as possible manifestations of lymphoproliferation included lymphadenopathy, lymphoid hyperplasia, lymphocytic inflammation, lymphocytosis, and gammopathies. RESULTS: Among 1565 CVID patients, lymphoproliferation was reported in 16% (N5242). Of these 242 patients, 19 (8%) also had a diagnosis of lymphoma, while the remaining 221 (92%) did not. Lymphoproliferative conditions reported among CVID patients included lymphadenopathy (N5192, 12.3%), lymphoid hyperplasia or lymphocytic inflammation (N557, 2.6%), lymphocytosis (N53, 0.2%), and gammopathies (N512, 0.8%). Lymphoid hyperplasia was most commonly reported as being pulmonary (N525, 1.6%), followed by non-specific (N522, 1.4%), and intestinal (N516, 1%).Gammopathies included monoclonal gammopathy (N59, 0.6%), multiple myeloma (N52, 0.1%), polyclonal gammopathy (N51), and light chain disease (N51 Pediatrics, Division of Allergy and Immunology, Northwell Health System, Hofstra School of Medicine, Great Neck, NY. RATIONALE: Treatment-refractory moderate/severe atopic dermatitis (MSAD) raises concerns for an underlying immunodeficiency. Sporadic reports of transient hypogammaglobulinemia of infancy(THI) associated with MSAD were found in the literature. However, we aim to compare a comprehensive immunologic evaluation and assess duration of THI in patients with MSAD (ADcTHI) compared to patients with MSAD and normal IgG levels (ADsTHI) and the literature reported THI population. METHODS: A case-control retrospective chart review was conducted at a single academic center for patients with MSAD and/or hypogammaglobulinemia using their ICD9/ICD10 codes, respectively. All available immunological laboratory data were collected. Descriptive statistical analysis was utilized for comparison. RESULTS: 8 disease(ADcTHI) and 29 control cases(ADsTHI) met inclusion criteria. The 8 disease cases had a median age of 5 months and median IgG of 153.5 mg/dL at initial presentation. The 29 controls had a median age of 16 months and median IgG of 736.00 mg/dL at initial presentation. At follow-up, 50% of cases had normalization of IgG and 50% had up-trending IgG at a median age of 13 months with AD treatment. The controls had more infections than affected patients, 3.0 vs. 1.0 infections respectively. Median albumin and total protein for both groups were very similar. CONCLUSIONS: ADcTHI is not associated with increased risks of infection or malnutrition in comparison with ADsTHI. Furthermore, when compared with classical THI described in the literature, THI with MSAD is a milder variant without significant infectious complications and earlier time to resolution. Further studies are necessary to elucidate the mechanism leading to hypogammaglobulinemia in MSAD patients.
